Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash from Investing Activities: 2017-2025

Historic Cash from Investing Activities for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $506,000.

  • Puma Biotechnology's Cash from Investing Activities rose 95.37% to $506,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year increase of 56.14%. This contributed to the annual value of -$20.4 million for FY2024, which is 6.87% down from last year.
  • Puma Biotechnology's Cash from Investing Activities amounted to $506,000 in Q3 2025, which was up 104.50% from -$11.2 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Cash from Investing Activities peaked at $11.2 million during Q3 2023, and registered a low of -$19.1 million during Q1 2024.
  • For the 3-year period, Puma Biotechnology's Cash from Investing Activities averaged around -$4.4 million, with its median value being -$2.3 million (2024).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first surged by 278.93% in 2022, then crashed by 1,700.00% in 2025.
  • Quarterly analysis of 5 years shows Puma Biotechnology's Cash from Investing Activities stood at $4.6 million in 2021, then tumbled by 356.94% to -$11.9 million in 2022, then skyrocketed by 31.19% to -$8.2 million in 2023, then surged by 71.60% to -$2.3 million in 2024, then soared by 95.37% to $506,000 in 2025.
  • Its last three reported values are $506,000 in Q3 2025, -$11.2 million for Q2 2025, and $1.5 million during Q1 2025.